RxDoctor Payments Data

Vinisha Patel, MD

Internal Medicine · Bellaire, TXNPI 1891808291

Payments from drug & device makers

$3,172in general payments, 2019–2025

Across 133 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$831
  • Abbott$452
  • Lilly USA, LLC$336
  • Exact Sciences$275
  • GSK$249
  • Novo Nordisk$235
  • plus $795 from 19 others

What the payments were for

  • Food & beverage$3,172100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,172 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$183,370
Medicare patients
470
Services billed
1,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide73$107,932
OzempicSemaglutide66$105,979
EliquisApixaban56$74,650
JardianceEmpagliflozin41$59,009
XareltoRivaroxaban16$26,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$25,357
FarxigaDapagliflozin Propanediol13$21,812
LinzessLinaclotide11$16,667
TrulicityDulaglutide12$13,596
Rosuvastatin Calcium464$7,425
SynthroidLevothyroxine Sodium90$7,128
Atorvastatin Calcium653$7,015
SymbicortBudesonide/Formoterol Fumarate12$6,750
AbrysvoRsv Vacc, Pref A And Pref B/Pf18$5,699
Levothyroxine Sodium465$5,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$336$121,52885 claims
Novo NordiskOzempic$235$105,97966 claims
Boehringer IngelheimJardiance$41$59,00941 claims
AstraZenecaFarxiga, Symbicort$87$28,56225 claims
GSKTrelegy Ellipta$249$25,35730 claims
AbbVieLinzess, Synthroid$19$23,795101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →